Heartseed
Near-clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiomyocytes for heart failure.
Launch date
Employees
Market cap
-
Enterprise valuation
$185m (Public information from May 2023)
Tokyo Japan (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
* | JPY100m | Seed | |
N/A | JPY250m | Series A | |
N/A | JPY250m | Series A | |
$7.2m | Series A | ||
$26.0m | Series B | ||
N/A | $960k | Early VC | |
N/A | JPY77.0m | Series B | |
$37.0m | Series C | ||
* | $14.4m Valuation: $185m | Series D | |
Total Funding | $90.8m |